Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 3/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | UBE2M | P61081 | 1/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897576 | 0.86 | CYP2C19 (0.67) | TACR3SIGMAR1ALDH1A1KDM4ECYP2C19 | |
| SCHEMBL4631243 | 0.85 | POLB (0.64) | TACR3OPRL1DRD4TACR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9317938 | 0.84 | POLB (0.62) | TACR3OPRL1DRD4TACR1ALDH1A1 | |
| SCHEMBL4815864 | 0.83 | OPRM1 (0.55) | TACR3OPRL1DRD4TACR1FAAH | |
| SCHEMBL2932067 | 0.83 | ALDH1A1 (0.51) | TACR3OPRL1CHRM4TACR1ALDH1A1 | |
| SCHEMBL3911069 | 0.81 | TACR3 (0.55) | TACR3SIGMAR1DRD4TACR1ALDH1A1 | |
| SCHEMBL3126554 | 0.81 | OPRL1 (0.62) | OPRL1CHRM4SIGMAR1DRD4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27626948 | 0.80 | OPRL1 (0.55) | OPRL1CHRM4SIGMAR1DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL4814838 | 0.80 | OPRL1 (0.55) | OPRL1CHRM4SIGMAR1DRD4ALDH1A1 | |
| SCHEMBL2872518 | 0.80 | DPP4 (0.48) | OPRL1CHRM4SIGMAR1TACR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101006084-B | 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof | SANOFI AVENTIS | 2010-09-08 | — | — | CN | disclosed |
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7294628-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| CN-101006084-A | 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof | SANOFI AVENTIS (FR) | 2007-07-25 | — | — | CN | disclosed |
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| EP-1773823-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| EP-1513835-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-08-16 | — | — | EP | disclosed |
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | US | disclosed |
| EP-1513836-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006021654-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-03-02 | — | — | WO | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| EP-1513836-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1513835-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104225-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104226-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C2, NR3C1 | TACR3 256/4885OPRL1 29/4885CHRM4 183/4885 |
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | ADRB3, ADRA2C, OPRK1 | TACR3 343/4885OPRL1 9/4885CHRM4 149/4885 |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | TACR3 380/4885OPRL1 24/4885CHRM4 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.